Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 2/20 | 0.46 |
| ▸ | ACHE | P22303 | 3/20 | 0.45 |
| ▸ | DRD2 | P14416 | 6/20 | 0.45 |
| ▸ | DRD4 | P21917 | 6/20 | 0.45 |
| ▸ | DRD3 | P35462 | 5/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.43 |
| ▸ | BCHE | P06276 | 2/20 | 0.43 |
| ▸ | BACE1 | P56817 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | CCR2 | P41597 | 1/20 | 0.42 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14545335 | 0.94 | ACHE (0.49) | ACHEDRD2DRD4DRD3ROCK1 | |
| SCHEMBL14545566 | 0.81 | ESR1 (0.43) | — | |
| SCHEMBL14545603 | 0.79 | MET (0.43) | DRD4ALDH1A1 | |
| SCHEMBL4693991 | 0.78 | PIK3CD (0.43) | MCHR1KCNH2 | |
| SCHEMBL14544975 | 0.77 | ACHE (0.55) | ACHEDRD2DRD4DRD3ROCK1 | |
| SCHEMBL14545007 | 0.77 | ACHE (0.55) | ACHEDRD2DRD4DRD3ROCK1 | |
| SCHEMBL10607203 | 0.76 | HRH3 (0.60) | MCHR1ACHEROCK1ROCK2BCHE | |
| SCHEMBL14545592 | 0.76 | CNR1 (0.43) | — | |
| Hydrochloric Acid SCHEMBL10608924 | 0.75 | GAA (0.61) | MCHR1ACHEROCK1ROCK2BCHE | |
| SCHEMBL14545572 | 0.74 | ACHE (0.62) | MCHR1ACHEDRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070078135-A1 | Substituted heteroaryl CB1 antagonists | NEUROGEN CORPORATION (US) | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078135-A1 | Substituted heteroaryl CB1 antagonists | CNR1, CNR2, OPRL1 | MCHR1 132/4885ACHE 1931/4885DRD2 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.